Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
Realtor Runwal Developers approaches Sebi to mobilise Rs 2,000 cr via IPO
1er/10/2025
Shankar Sharma says India, US exposure at lowest in 30 years, remains bearish on indices
1er/10/2025
SIPs for first-timers, lumpsums for veterans in JioBlackRock Flexi Cap Fund : Rishi Kohli
1er/10/2025
As gold, silver soar, Gurmeet Chadha warns investors : ‘Don’t get carried away’. Here’s why
1er/10/2025
Central Asia's maiden crypto fund launched in Kazakhstan
1er/10/2025
Nithin Kamath weighs in again on Zerodha strategy if weekly options scrapped
1er/10/2025
